Table 2.
Baseline main metabolic characteristics of HIV-infected patients based on rs10892151 genotype and treatment strategy
| PI-treated patients (n = 95) |
NNRTI-treated patients (n = 113) |
|||
|---|---|---|---|---|
| G/G carriers (n = 87) |
A/G carriers (n = 8) |
G/G carriers (n = 103) |
A/G carriers (n = 10) |
|
| BMI, kg/m2 | 22.9 (3.1) | 23.4 (3.2) | 22.6 (2.9) | 23.1 (3.1) |
| ApoC-III, μg/mL | 11.12 (5.1) | 10.62 (4.6) | 11.39 (4.9) | 10.26 (4.8) |
| Total cholesterol, mmol/L | 4.91 (1.3) | 5.06 (1.3) | 4.87 (1.2) | 4.60 (1.2) |
| HDL-cholesterol, mmol/L | 1.02 (0.4) | 1.06 (0.4) | 1.09 (0.4) | 1.1 (0.4) |
| VLDL-cholesterol, mmol/L | 0.82 (0.2) | 0.54 (0.1) | 0.91 (0.4) | 0.72 (0.3) |
| LDL-cholesterol, mmol/L | 2.82 (0.8) | 2.87 (0.9) | 2.88 (0.9) | 2.95 (0.9) |
| Triglycerides, mmol/L | 2.65 (2.1) | 2.78 (2.2) | 2.34 (2.2) | 2.10 (2.1) |
| Glucose, mmol/L | 5.68 (1.0) | 5.95 (0.9) | 5.15 (0.9) | 5.16 (0.9) |
| CRP, mg/L | 4.6 (5.4) | 5.1 (5.6) | 3.73 (5.5) | 4.76 (5.7) |
| MCP-1, pg/mL | 73.31 (40.3) | 78.76 (43.8) | 75.92 (42.1) | 83.10 (44.8) |
Values are the mean and the standard deviation (SD), unless otherwise indicated. BMI, body-mass index; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcritase inhibitor